The country is closely watching how the battle over abortion medication unfolds in federal courts. It follows a Texas judge’s decision to overturn FDA approval of the mifepristone. But there’s also growing concern over what that ruling could mean for the drug approval process in general. Amna Nawaz discussed what’s at stake with Dr. Joshua Sharfstein, the former FDA principal deputy commissioner.